Abstract: The present invention relates to a novel multilayered assembly for the prolonged delayed and controlled diffusion of an active agent or a drug, in particular into an aqueous medium. In particular, the present invention relates to a nano-sized drug delivery structure comprising at least one support material; one multilayered structure overlaying and/or surrounding at least partially said support material and comprising at least two layers of oppositely charged materials; and one drug active agent conjugated by means of a disulphide bond on one or more negatively charged material(s) of one or more inner layer(s) of the said multilayered structure. Such a nano-sized drug delivery structure is more particularly useful for the manufacture of pharmaceutical compositions, for example intended to be used in cancer therapy. Internalization of the drug nanostructures into cancer cells, retardation of diffusion of the active drug, activity and specific targeting of the drug nanostructures were tested.

Abstract: The present invention relates to methods and pharmaceutical compositions for treating breast cancers. In particular, the present invention relates to a method for predicting the survival of a patient suffering from a breast cancer comprising i) determining the expression level of Vangl2 in a tumor sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) providing a poor prognosis when the expression level determined at step i) is higher than the predetermined reference value. The present invention also relates to a method for treating a patient suffering from a breast cancer comprising the steps consisting of i) predicting the survival of the patient according to claim 1 and ii) administering the patient with an anti-Vangl2 antibody or an inhibitor of Vangl2 expression or an inhibitor of the Vangl2-p62 interaction when it is concluded that the patient has a poor prognosis at step i).